|
US4766106A
(en)
|
1985-06-26 |
1988-08-23 |
Cetus Corporation |
Solubilization of proteins for pharmaceutical compositions using polymer conjugation
|
|
US5206344A
(en)
|
1985-06-26 |
1993-04-27 |
Cetus Oncology Corporation |
Interleukin-2 muteins and polymer conjugation thereof
|
|
US6362325B1
(en)
|
1988-11-07 |
2002-03-26 |
Advanced Research And Technology Institute, Inc. |
Murine 4-1BB gene
|
|
US6303121B1
(en)
|
1992-07-30 |
2001-10-16 |
Advanced Research And Technology |
Method of using human receptor protein 4-1BB
|
|
US4902502A
(en)
|
1989-01-23 |
1990-02-20 |
Cetus Corporation |
Preparation of a polymer/interleukin-2 conjugate
|
|
US5089261A
(en)
|
1989-01-23 |
1992-02-18 |
Cetus Corporation |
Preparation of a polymer/interleukin-2 conjugate
|
|
US5279833A
(en)
|
1990-04-04 |
1994-01-18 |
Yale University |
Liposomal transfection of nucleic acids into animal cells
|
|
PT672141E
(pt)
|
1992-10-23 |
2003-09-30 |
Immunex Corp |
Metodos de preparacao de proteinas oligomericas soluveis
|
|
GB9317380D0
(en)
|
1993-08-20 |
1993-10-06 |
Therexsys Ltd |
Transfection process
|
|
US5821332A
(en)
|
1993-11-03 |
1998-10-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Receptor on the surface of activated CD4+ T-cells: ACT-4
|
|
US6989434B1
(en)
|
1994-02-11 |
2006-01-24 |
Invitrogen Corporation |
Reagents for intracellular delivery of macromolecules
|
|
US5691188A
(en)
|
1994-02-14 |
1997-11-25 |
American Cyanamid Company |
Transformed yeast cells expressing heterologous G-protein coupled receptor
|
|
WO1996000295A1
(en)
|
1994-06-27 |
1996-01-04 |
The Johns Hopkins University |
Targeted gene delivery system
|
|
US5908635A
(en)
|
1994-08-05 |
1999-06-01 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method for the liposomal delivery of nucleic acids
|
|
US5484720A
(en)
|
1994-09-08 |
1996-01-16 |
Genentech, Inc. |
Methods for calcium phosphate transfection
|
|
US5830430A
(en)
|
1995-02-21 |
1998-11-03 |
Imarx Pharmaceutical Corp. |
Cationic lipids and the use thereof
|
|
DE69624436T2
(de)
|
1995-04-08 |
2003-08-28 |
Lg Chemical Ltd., Seoul/Soul |
Humaner 4-1bb spezifischer humaner antikörper und diesen produzierende zellinie
|
|
US5981501A
(en)
|
1995-06-07 |
1999-11-09 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating plasmids in lipid bilayers
|
|
US5849902A
(en)
|
1996-09-26 |
1998-12-15 |
Oligos Etc. Inc. |
Three component chimeric antisense oligonucleotides
|
|
IL129138A0
(en)
|
1996-10-11 |
2000-02-17 |
Bristol Myers Squibb Co |
Methods and compositions for immunomodulation
|
|
JP2001508302A
(ja)
|
1997-01-10 |
2001-06-26 |
ライフ テクノロジーズ,インコーポレイテッド |
胚性幹細胞血清置換
|
|
DK0973928T3
(da)
|
1997-03-11 |
2010-08-09 |
Univ Minnesota |
DNA-baseret transposonsystem til indføring af nukleinsyre i DNA i en celle
|
|
US6475994B2
(en)
|
1998-01-07 |
2002-11-05 |
Donald A. Tomalia |
Method and articles for transfection of genetic material
|
|
US6312700B1
(en)
|
1998-02-24 |
2001-11-06 |
Andrew D. Weinberg |
Method for enhancing an antigen specific immune response with OX-40L
|
|
US7189705B2
(en)
|
2000-04-20 |
2007-03-13 |
The University Of British Columbia |
Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
|
|
US6627442B1
(en)
|
2000-08-31 |
2003-09-30 |
Virxsys Corporation |
Methods for stable transduction of cells with hiv-derived viral vectors
|
|
EP2316490A3
(en)
|
2000-10-31 |
2012-02-01 |
PR Pharmaceuticals, Inc. |
Methods and compositions for enhanced delivery of bioactive molecules
|
|
ES2295639T3
(es)
|
2002-06-13 |
2008-04-16 |
Crucell Holland B.V. |
Agonistas del receptor ox40=(=cd134) y uso terapeutico descripcion.
|
|
JP2006500921A
(ja)
|
2002-07-30 |
2006-01-12 |
ブリストル−マイヤーズ スクイブ カンパニー |
ヒト4−1bbに対するヒト化抗体
|
|
CN101120083B
(zh)
|
2003-10-08 |
2013-03-27 |
威尔森沃尔夫制造公司 |
利用透气性材料进行细胞培养的方法及装置
|
|
US7288638B2
(en)
|
2003-10-10 |
2007-10-30 |
Bristol-Myers Squibb Company |
Fully human antibodies against human 4-1BB
|
|
CN101072578A
(zh)
|
2004-10-29 |
2007-11-14 |
南加州大学 |
用共刺激分子的联合癌症免疫疗法
|
|
EP1877090B1
(en)
|
2005-05-06 |
2014-01-15 |
Providence Health System |
Trimeric ox40-immunoglobulin fusion protein and methods of use
|
|
EP3530736A3
(en)
|
2005-05-09 |
2019-11-06 |
ONO Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
|
TWI466269B
(zh)
|
2006-07-14 |
2014-12-21 |
Semiconductor Energy Lab |
非揮發性記憶體
|
|
EP1894940A1
(en)
|
2006-08-28 |
2008-03-05 |
Apogenix GmbH |
TNF superfamily fusion proteins
|
|
KR20100014588A
(ko)
|
2007-02-27 |
2010-02-10 |
제넨테크, 인크. |
길항제 ox40 항체 및 염증성 및 자가면역 질환의 치료에서의 이의 용도
|
|
EP2484691B1
(en)
|
2007-07-10 |
2016-01-13 |
Apogenix GmbH |
TNF superfamily collectin fusion proteins
|
|
WO2009045457A2
(en)
|
2007-10-02 |
2009-04-09 |
Rxi Pharmaceuticals Corp. |
Tripartite rnai constructs
|
|
SI2242771T1
(sl)
|
2007-12-14 |
2013-09-30 |
Bristol-Myers Squibb Company |
Vezane molekule k humanemu ox40 receptorju
|
|
EP3643782A1
(en)
|
2008-02-11 |
2020-04-29 |
Phio Pharmaceuticals Corp. |
Modified rnai polynucleotides and uses thereof
|
|
EP2310409A2
(en)
|
2008-06-17 |
2011-04-20 |
Apogenix GmbH |
Multimeric tnf receptors
|
|
PL2604693T3
(pl)
|
2008-07-21 |
2016-09-30 |
|
Jednołańcuchowe cząsteczki TNFSF
|
|
EP2342340A1
(en)
|
2008-09-22 |
2011-07-13 |
Rxi Pharmaceuticals Corporation |
Rna interference in skin indications
|
|
WO2010042433A1
(en)
|
2008-10-06 |
2010-04-15 |
Bristol-Myers Squibb Company |
Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
|
|
WO2010078966A1
(en)
|
2009-01-09 |
2010-07-15 |
Apogenix Gmbh |
Fusion proteins forming trimers
|
|
US20130115617A1
(en)
|
2009-12-08 |
2013-05-09 |
John R. Wilson |
Methods of cell culture for adoptive cell therapy
|
|
WO2011072088A2
(en)
|
2009-12-08 |
2011-06-16 |
Wilson Wolf Manufacturing Corporation |
Improved methods of cell culture for adoptive cell therapy
|
|
US8956860B2
(en)
|
2009-12-08 |
2015-02-17 |
Juan F. Vera |
Methods of cell culture for adoptive cell therapy
|
|
US9095504B2
(en)
|
2010-03-24 |
2015-08-04 |
Rxi Pharmaceuticals Corporation |
RNA interference in ocular indications
|
|
WO2011119852A1
(en)
|
2010-03-24 |
2011-09-29 |
Rxi Pharmaceuticals Corporation |
Reduced size self-delivering rnai compounds
|
|
CA2794189C
(en)
|
2010-03-24 |
2022-01-11 |
Rxi Pharmaceuticals Corporation |
Rna interference in dermal and fibrotic indications
|
|
LT2609118T
(lt)
|
2010-08-23 |
2017-04-25 |
Board Of Regents, The University Of Texas System |
Anti-ox40 antikūnai ir jų panaudojimo būdai
|
|
NZ729044A
(en)
|
2010-09-09 |
2020-07-31 |
Pfizer |
4-1bb binding molecules
|
|
US8962804B2
(en)
|
2010-10-08 |
2015-02-24 |
City Of Hope |
Meditopes and meditope-binding antibodies and uses thereof
|
|
ES2866674T3
(es)
|
2010-11-12 |
2021-10-19 |
Nektar Therapeutics |
Conjugados de una fracción de IL-2 y un polímero
|
|
US20120244133A1
(en)
|
2011-03-22 |
2012-09-27 |
The United States of America, as represented by the Secretary, Department of Health and |
Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
|
|
WO2012177788A1
(en)
|
2011-06-20 |
2012-12-27 |
La Jolla Institute For Allergy And Immunology |
Modulators of 4-1bb and immune responses
|
|
WO2013016600A2
(en)
|
2011-07-28 |
2013-01-31 |
The Trustees Of The University Of Pennsylvania |
Methods and reagents for diagnosing conditions and characterization of tumor cells associated with serous fluids
|
|
JP6038920B2
(ja)
|
2011-08-23 |
2016-12-07 |
ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム |
抗ox40抗体およびそれを使用する方法
|
|
KR20140060541A
(ko)
|
2011-09-16 |
2014-05-20 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
암을 치료하기 위한 rna 조작된 t 세포
|
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
|
WO2013059343A1
(en)
|
2011-10-17 |
2013-04-25 |
Massachusetts Institute Of Technology |
Intracellular delivery
|
|
CN104379727A
(zh)
|
2012-05-18 |
2015-02-25 |
威尔逊沃夫制造公司 |
改进的用于过继细胞治疗的细胞培养方法
|
|
US9156897B2
(en)
|
2012-06-08 |
2015-10-13 |
Alkermes, Inc. |
Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
|
|
CN110241086A
(zh)
|
2012-06-11 |
2019-09-17 |
威尔逊沃夫制造公司 |
用于过继细胞疗法的改进的细胞培养方法
|
|
WO2014133567A1
(en)
|
2013-03-01 |
2014-09-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of producing enriched populations of tumor-reactive t cells from tumor
|
|
RS57840B1
(sr)
|
2013-03-18 |
2018-12-31 |
Biocerox Prod Bv |
Humanizovana anti-cd 134 (ox40) antitela i njihove upotrebe
|
|
SG10201705494YA
(en)
|
2013-06-24 |
2017-08-30 |
Wolf Wilson Mfg Corp |
Closed system device and methods for gas permeable cell culture process
|
|
JP6772062B2
(ja)
|
2013-12-02 |
2020-10-21 |
フィオ ファーマシューティカルズ コーポレーションPhio Pharmaceuticals Corp. |
癌の免疫療法
|
|
MX2016007965A
(es)
|
2013-12-17 |
2016-10-28 |
Genentech Inc |
Terapia de combinacion que comprende agonistas de union a ox40 y antagonistas de union al eje pd-1.
|
|
US10899840B2
(en)
|
2014-02-04 |
2021-01-26 |
Pfizer Inc. |
Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
|
|
UA123821C2
(uk)
|
2014-06-11 |
2021-06-09 |
Полібіосепт Гмбх |
Композиція для експансії лімфоцитів in vitro
|
|
US10544392B2
(en)
*
|
2015-05-01 |
2020-01-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
|
|
JP6925984B2
(ja)
|
2015-07-09 |
2021-08-25 |
マサチューセッツ インスティテュート オブ テクノロジー |
無核細胞への物質の送達
|
|
US11021707B2
(en)
|
2015-10-19 |
2021-06-01 |
Phio Pharmaceuticals Corp. |
Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA
|
|
EP3402890B1
(en)
|
2016-01-12 |
2025-01-01 |
SQZ Biotechnologies Company |
Intracellular delivery of complexes
|
|
CN110099998A
(zh)
|
2016-10-26 |
2019-08-06 |
艾欧凡斯生物治疗公司 |
冷冻保存的肿瘤浸润淋巴细胞的再刺激
|
|
CA3043597A1
(en)
|
2016-11-10 |
2018-05-17 |
Nektar Therapeutics |
Immunotherapeutic tumor treatment method
|
|
AU2018207283C1
(en)
|
2017-01-10 |
2024-05-02 |
Nektar Therapeutics |
Multi-arm polymer conjugates of TLR agonist compounds and related immunotherapeutic treatment methods
|
|
JOP20190224A1
(ar)
|
2017-03-29 |
2019-09-26 |
Iovance Biotherapeutics Inc |
عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
|
|
KR102920712B1
(ko)
|
2017-05-24 |
2026-01-30 |
노파르티스 아게 |
항체-사이토카인 생착된 단백질 및 암 치료에 있어서의 사용 방법
|
|
ES3000510T3
(en)
*
|
2017-06-09 |
2025-02-28 |
Providence Health & Services Oregon |
Tumor-infiltrating t-cells for use in the treatment of cancer
|
|
IL321812A
(en)
|
2017-08-03 |
2025-08-01 |
Synthorx Inc |
Cytokine complexes for the treatment of autoimmune diseases
|
|
JP7557367B2
(ja)
*
|
2017-11-17 |
2024-09-27 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
細針吸引及び小生検からのtil拡大培養
|
|
EP3737743A1
(en)
|
2018-01-08 |
2020-11-18 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
|
NL2020422B1
(en)
|
2018-02-12 |
2019-08-19 |
Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis |
Methods for Predicting Treatment Outcome and/or for Selecting a Subject Suitable for Immune Checkpoint Therapy.
|
|
WO2019210131A1
(en)
*
|
2018-04-27 |
2019-10-31 |
Iovance Biotherapeutics, Inc. |
Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
IL282775B1
(en)
*
|
2018-11-05 |
2026-05-01 |
Iovance Biotherapeutics Inc |
Selection of enhanced carrier-reactive T cells
|
|
MA54952A
(fr)
|
2019-02-06 |
2022-05-11 |
Synthorx Inc |
Conjugués d'il-2 et méthodes d'utilisation de ceux-ci
|
|
US11246906B2
(en)
|
2019-06-11 |
2022-02-15 |
Alkermes Pharma Ireland Limited |
Compositions and methods for subcutaneous administration of cancer immunotherapy
|